Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ELUT 
Elutia Inc. (ELUT)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/14/2025: ELUT (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $4
1 Year Target Price $4
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -64.49% | Avg. Invested days 19 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 38.36M USD | Price to earnings Ratio - | 1Y Target Price 4 |
Price to earnings Ratio - | 1Y Target Price 4 | ||
Volume (30-day avg) 2 | Beta 0.78 | 52 Weeks Range 0.85 - 5.12 | Updated Date 10/14/2025 |
52 Weeks Range 0.85 - 5.12 | Updated Date 10/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.43 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -90.01% | Operating Margin (TTM) -93.74% |
Management Effectiveness
Return on Assets (TTM) -37.27% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 57782339 | Price to Sales(TTM) 1.62 |
Enterprise Value 57782339 | Price to Sales(TTM) 1.62 | ||
Enterprise Value to Revenue 2.44 | Enterprise Value to EBITDA -3.32 | Shares Outstanding 38081935 | Shares Floating 15623531 |
Shares Outstanding 38081935 | Shares Floating 15623531 | ||
Percent Insiders 2.35 | Percent Institutions 70.65 |
Upturn AI SWOT
Elutia Inc.
Company Overview
History and Background
Elutia Inc., formerly known as Conformis, Inc., was founded in 2004. Initially focused on personalized knee implants, it has evolved to offer a broader portfolio of biomaterials and surgical solutions for orthopedics and wound care. It underwent a rebranding to Elutia in 2023, reflecting its expanded focus.
Core Business Areas
- Orthopedics: Development and commercialization of surgical solutions for joint preservation, repair, and replacement, including personalized knee and hip solutions, tissue regeneration and orthopedic implants.
- Wound Care: Development and commercialization of advanced wound care products, including skin substitutes and biologics, for chronic and acute wounds.
- Biomaterials: Manufacturing and distribution of resorbable biomaterials for a variety of surgical applications.
Leadership and Structure
As of November 2024, the CEO is Terrence D. Loftus. The company operates with a functional organizational structure, with departments dedicated to research and development, manufacturing, sales and marketing, finance, and operations.
Top Products and Market Share
Key Offerings
- Biobrane: Biobrane is a biosynthetic wound dressing used as a temporary skin substitute, primarily for burn wounds. Competitors include Integra LifeSciences (Integra), Smith+Nephew (REGENESISu2122 MicroMatrixu00ae), and Mallinckrodt (StrataGraftu00ae). Market share data not readily available, but Biobrane is a key revenue driver. Revenue not specifically broken out.
- PariGenix DBM: PariGenix DBM is a resorbable bone void filler used in orthopedic surgical procedures. Competitors include Medtronic (Infuse), Zimmer Biomet (Grafton), and Stryker (Vitoss). Market share data not readily available. Revenue not specifically broken out.
- Conformis Personalized Knee Replacement: Personalized knee replacement implants designed to match a patient's unique anatomy. The competitors are Depuy Synthes, Stryker, Zimmer Biomet. Market share data not readily available. Revenue not specifically broken out.
Market Dynamics
Industry Overview
The market Elutia operates in comprises orthopedic implants, wound care, and biomaterials which is highly competitive and heavily influenced by technological advancements, regulatory approvals, and demographic trends (aging population, increasing obesity).
Positioning
Elutia differentiates itself through its focus on personalized surgical solutions and advanced biomaterials. They seek to capture market share by addressing unmet needs in orthopedics and wound care through unique product offerings and technological innovation.
Total Addressable Market (TAM)
The global orthopedic devices market is projected to reach USD 60 billion. The advanced wound care market is projected to reach USD 25 billion. Elutia is positioned to capture a portion of these markets with its targeted product portfolio. Specific percentage of TAM targetted is unavailable.
Upturn SWOT Analysis
Strengths
- Innovative product portfolio
- Strong intellectual property portfolio
- Focus on unmet clinical needs
- Experienced management team
Weaknesses
- Limited sales and marketing infrastructure
- Dependence on key products
- History of operating losses
- Relatively small market share compared to major players
Opportunities
- Expansion into new geographic markets
- Acquisition of complementary technologies
- Partnerships with larger medical device companies
- Increasing demand for minimally invasive surgical procedures
Threats
- Intense competition from established players
- Regulatory hurdles
- Product liability claims
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- Zimmer Biomet (ZBH)
- Stryker (SYK)
- Medtronic (MDT)
- Integra LifeSciences (IART)
- Smith+Nephew (SNN)
Competitive Landscape
Elutia faces intense competition from larger, more established players. Elutia's advantage lies in its targeted solutions for specific niche areas. The company's smaller size allows for agility and focused innovation, but it also limits its resources.
Major Acquisitions
MTF Biologics Assets
- Year: 2023
- Acquisition Price (USD millions): 16
- Strategic Rationale: The MTF Biologics acquisition of certain soft tissue assets diversified the product offering and expanded access to the market.
Growth Trajectory and Initiatives
Historical Growth: Historically, the company has experienced erratic growth. Periods of high revenue gains are followed by plateaus and contractions, reflecting market acceptance of its new products and its transition away from a highly niche implant-centric business to broader biomaterials
Future Projections: Analyst estimates suggest continued revenue growth driven by increased adoption of Biobrane and PariGenix, as well as international expansion. Profitability is projected to improve as the company achieves economies of scale.
Recent Initiatives: Recent initiatives include the expansion of the Biobrane product line, strategic partnerships with distributors, and efforts to reduce operating expenses.
Summary
Elutia demonstrates innovation through its product portfolio with considerable experience in biomaterials and personalized surgical solutions; however, it's challenged by a relatively limited sales and marketing resources, and significant debt. The company has an opportunity to leverage unmet clinical needs by capitalizing on expansion into new geographic markets and partnerships with larger medical device companies. Elutia should watch for intense competition from established players and regulatory hurdles.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- SEC Filings (10-K, 10-Q)
- Analyst Reports
- Market Research Reports
- Yahoo Finance
Disclaimers:
This analysis is based on publicly available information and is not financial advice. Market conditions and company performance can change rapidly. Consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Elutia Inc.
Exchange NASDAQ | Headquaters Silver Spring, MD, United States | ||
IPO Launch date 2023-09-07 | Co-Founder, President, CEO & Director Dr. C. Randal Mills Ph.D. | ||
Sector Healthcare | Industry Medical Devices | Full time employees 51 | Website https://elutia.com |
Full time employees 51 | Website https://elutia.com | ||
Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.